Planned, ongoing and recently completed clinical trials for atherosclerosis prevention and regression: an update

Bibliography

• THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY GROUP: Randomized trial of cholesterol lovwring in 4444 patients with coronary heart disease: the Scandi-navian Simvastatin Survival Study (4S). Lancet (1994) 344:1383–1389.
   PubMed Web of Science ®Google Scholar
• SHEPHERD J, COBBE SM, FORD I et al.: Prevention ofcoronary heart disease with pravastatin in men with hyper cholesterolemia. New Engl. J. Med. (1995) 333 (20):1301–1307.
   PubMed Web of Science ®Google Scholar
• SACKS FM, PFEFFER MA, MOYE LA et al FOR THE CHO-LESTEROL AND RECURRENT EVENTS TRIAL INVESTIGA-TORS: The effect of pravastatin oncoronary events after myocardial infarction in patients with average choles-terol levels. New Engl. J. Med. (1996) 335:1001–1009.
   PubMed Web of Science ®Google Scholar
• BYINGTON RP, JUKEMA JW, SALONEN JT et al: Reductionin cardiovascular events of the pravastatin atherosclerosis intervention program. Circulation (1995) 92:2419–2425.
   PubMed Web of Science ®Google Scholar
• MIETTINEN TA, PEDERSEN T, PYLRALA K, KJEKSHUS J:Cholesterol lowering with simvastatin reduced major coronary events, revascularization procedures and car-diovascular hospitalizations in women participating in the Scandinavian Simvastatin Survival Study (4S). Cir-culation (1996) 9410068.
   Google Scholar
• CTL Collaborative Meeting. American Heart Association(1996).
   Google Scholar
• Scientific presentations. LIPID Annual Meeting. Queen-stown, New Zealand (1996).
   Google Scholar
• BRISTOL-MYERS SQUIBB: Data on file.
   Google Scholar
• LEWIS, SJ, MITCHELL JS, EAST C et al: Women in CARE have earlier and greater response to pravastatin post myocardial infarction. Circulation (1996) 9410069.
   Google Scholar
• GOLDBERG R, SACKS F, HOWARD B et al: Diabetic response to pravastatin during the CARE Study. Circu-lation (1996) 94:#3159.
   Google Scholar
• CHESNEY CM, HERD JA, ELAM MB et al: Niacin lowersfibrinogen in patients with peripheral artery disease (PAD). Circulation (1996) 94:#3419.
   Google Scholar
• BRISTOL-MYERS SQUIBB: GISSI IV. Internal communica-tion.
   Google Scholar
• THE LIPID STUDY GROUP: Design features and baselinecharacteristics of the LIPID (Long-term Intervention with Pravastatin in Ischemic Disease) Study: a random-ized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris. Am. J. Cardiol. (1995) 76:474–479.
   PubMed Web of Science ®Google Scholar
• JONES PH, GOTTO AM, Jr.: Extending the benefit of lipid-regulating therapy to primary prevention. Am. J. Cardiol. (1995) 76:118C–121C.
   Google Scholar
• RUBINS HB, ROBINS SJ, IWANE MK et al.: Rationale and design of the Department of Veterans Affairs high-den-sity lipoprotein secondary prevention of coronary ar-tery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cho-lesterol. Am. J. Cardiol. (1993) 71:45–52.
   PubMed Web of Science ®Google Scholar
• THE BEZAFIBRATE INFARCTION PREVENTION (BIN STUDY GROUP: Lipids and lipoproteins in symptomatic coronary heart disease. Circulation (1992) 86:829–848.
   Google Scholar
• DAVIS BR, CUTLER JA, GORDON DJ et al. FOR THE ALLHAT RESEARCH GROUP: Rationale and design for the Antihy-pertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am. J. Hypertens. (1996) 9:342–380.
   Google Scholar
• ELLIOTT WI ALLHAT - the largest and most important clinical trial in hypertension ever done in the USA. Am. Hypertens (1996) 9(4):409–411.
   PubMed Web of Science ®Google Scholar
• BLACK D: Personal communication.
   Google Scholar
• ROSSOUW, JE, FINNEGAN LP, HARLAN WR et al: The evolution of the Women's Health Initiative: perspec-tives from the NUL J. Am. Med. Worn. Assoc. (1995) 50(2)50–55.
   Google Scholar
• GOTTO AM: Sponsored Symposium. American Heart Asso-ciation (1996).
   Google Scholar
• CAMPEAU I, HUNNINGHAKE DB, HERD JA et al: Post-CABG clinical trial investigators. Atherosclerosis X Mont-real (October 1994)1243.
   Google Scholar
• Post CABG Trial: effects of cholesterol lowering and low intensity oral anticoagulation on late sapheinous vein graft status. Major Clinical Trials III Symposium. American College of Cardiologists Meeting (March 1996).
   Google Scholar
• SACKS FM, PASTERNAK RDC, GIBSON CM, ROSNER B, STONE PH: Effect on coronary atherosclerosis of de-crease in plasma cholesterol concentrations in normo-cholesterolemic patients. Lancet (1994) 344:1182–1186.
   PubMed Web of Science ®Google Scholar
• BLANKENHORN DH, AZEN SP, KRAMSCH DM et al. ANDTHE MARS RESEARCH GROUP: Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). Ann. Intern. Med. (1993) 119:969–979.
   Google Scholar
• HASKELL WL, ALDERMANN EL, FAIR JM eta].: Effects ofintensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). Circulation (1994) 89:975–990.
   Google Scholar
• WATERS D, HIGGINSON L, GLADSTONE P eta]. FOR THECCAIT STUDY GROUP: Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quanti-tative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation (1994) 89:959–968.
   Google Scholar
• CROUSE JR, BYINGTON RP, BOND MG et al.: Pravastatin, Lipids and Atherosclerosis inthe Carotid Arteries (PLAC II). Am. J. Cardiol. (1995) 75:455–459.
   PubMed Web of Science ®Google Scholar
• JUKEMA, JVV, BRUSCHKE AVG, VAN BOVEN AJ et al. ON BEHALF OF THE REGRESS STUDY GROUP: Effects of lipid lowering by pravastatin on progres sion and regression of serum cholesterol levels. Circulation (1995) 91:2528–2540.
   Google Scholar
• MAAS INVESTIGATORS: Effect of simvastatin on coro-nary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet (1994) 344:633–638.
   PubMed Web of Science ®Google Scholar
• PITT B, MANCINI BJ, ELLIS SG et al. FOR THE PLAC I INVESTIGATORS: Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC I): reduction in atherosclerosis progression and clinical events. jAm. Coll Cardiol. (1995) 26:1133–1129.
   PubMed Web of Science ®Google Scholar
• SALONEN JR, NYYSSONEN K, PORKKALA L eta].: Kuopio Atherosclerosis Prevention Study (KAPS): a population based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation (1995) 92:1756–1764.
   Google Scholar
• FURBERG CD, ADAMS HP, APPLEGATE WB et al FOR THE ASYMPTOMATIC CAROTID ARTERY PROGRESSION STUDY (ACAPS) RESEARCH GROUP: Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation (1994) 90:1679–1687.
   PubMed Web of Science ®Google Scholar
• MACMAHON S, SHARPE N, GAMBLE G et al. ON BEHALF OF THE LIPID STUDY RESEARCH GROUP: Effects of 4 years' treatment with pravastatin on carotid atherosclerosis inpatients with coronary heart disease: final results from the LIPID atherosclerosis substudy. Circulation (1996) 94:#3157.
   Google Scholar
• ERICSSON C-G, HAMSTEN A, NILSSON J et al: Angiog-rap hic assessment of effects of bezafibrate on progres-sion of coronary artery disease in young male postinfarction patients. Lancet (1996) 347:849–853.
   PubMed Web of Science ®Google Scholar
• SEVANNE M, NIEMINEN MS, TASKINEN M-R, FRICK MH: An angiographic secondary prevention trial with gemfi-brazil in post-bypass men with low plasma HDL-C concentrations: study design and baseline charac-teristics. Atherosclerosis X Montreal (October 1994)1244.
   Google Scholar
• RENSING UFE, BESTEHORN HP, PETERSEN J eta].: Simvas-tatin in the secondary prevention of coronary atherosclerosis. Atherosclerosis X Montreal (October 1994):#240.
   Google Scholar
• MAZZU AL, LATTIERI J, KAISER L, FREY R, HELLER AH: Ascending multiple dose safety, tolerability and phar - macodynamics of rivastatin in humans. Clin. Pharm aro'. Ther. (1993) 53:#210.
   Google Scholar
• ASHRAF T, HAY JW, CROUSE J eta].: Cost-effectiveness ofpravastatin in secondary prevention of coronary heart disease. Am. J. Cardiol. (1996) 78:409–414.
   Google Scholar
• PEDERSON TR, KJEKSHUS J, BOCCUZZI SJ, EPSTEIN RS:Clinical and resource utilization benefits of the Scandi-navian Simvas tat in Survival Study (4S) applied to the US population. Circulation (1995) 92:248S.
   Google Scholar
• JONSSON B, JOHANNESSON M, KJEKSHUS J eta].: Cost-ef-fectiveness of cholesterol-lowering - results from the Scandinavian Simvastatin Survival Study (4S). Eur. Heart J. (1996) 17:1001–1007.
   Google Scholar
• PEDERSEN TR,KJEKSHUS J, BOCCUZZI SJ, EPSTEIN RS: Clinical and resource utilization benefits of the Scandi-navian Simvastat in Survival Study (4S) applied to the US population. Circulation (1995) 92(8):2485.
   Web of Science ®Google Scholar
• PPP INVESTIGATORS: Design, rationale, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project - a combined analysis of three large-scale randomized trials:Long-term Intervention with Pravas - tatin in Ischemic Disease (LIPID), Cholesterol and Re-current Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS). Am. J. Cardiol. (1995) 76:899–905.
   PubMed Web of Science ®Google Scholar
• CHOLESTEROL TREATMENT TRIALIST COLLABORATION:Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens. Am. J. Cardiol. (1995) 75:1130–1134.
   PubMed Web of Science ®Google Scholar
• VAUGHAN CJ, MURPHY MB, BUCKLEY BM: Statins do more thanjust lower cholesterol. Lancet (1996) 348:1079–1082.
   PubMed Web of Science ®Google Scholar
• SUPERKO HR: Beyond LDL cholesterol reduction. Circu-lation (1996) 94:2351–2354.
   PubMed Web of Science ®Google Scholar
• MELLIES M, MCGOVERN ME: Ongoing and planned clini-cal trials for atherosclerosis prevention and regression. Exp. Opin. Invest Drugs (1994) 3(10:1189–1202.
   Google Scholar